ARCA Discovery, Inc. closed an $18M Series B led by Skyline Ventures and additional new investor InterWest Partners, previous investors Atlas Ventures, Boulder Ventures and the Peierls Foundation also participated in the round.
ARCA is aiming for an NDA submission in 2007 for Bucindolol, a next-generation beta-blocker and vasodilator for heart failure, and plans to seek approval of the drug concurrent with a genetic test to assist physicians in determining whether bucindolol is an appropriate therapy for their patients.
A targeted approach based upon genetic markers (beta-1 and alpha-2-c adrenergic receptors).
Colorado…at the forefront of personalized medicine!
No comments:
Post a Comment